{
    "nctId": "NCT02101879",
    "briefTitle": "Cardiotoxicity in Metastatic Her 2 Positive Patients Treated With Trastuzumab ,Pertuzumab and Taxanes",
    "officialTitle": "Cardiotoxicity in Metastatic Her 2 Positive Patients Treated With First Line Trastuzumab, Pertuzumab and Taxanes Based Regimen",
    "overallStatus": "UNKNOWN",
    "conditions": "Cardiotoxicity., Anti Her2 Therapy., Metastatic Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 20,
    "primaryOutcomeMeasure": "To assesses blood levels of TNI and BNP during the first four cycles Trastuzumab&Pertuzumab and Taxanes treatment",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Metastatic Breast Cancer patients with Her2 Positive Disease.\n* No prior treatment\n\nExclusion Criteria:\n\n* LEVF less than 50%",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}